Edgewise Therapeutics, Inc. is a pharmaceutical company that focuses on creating small molecule therapies for musculoskeletal diseases. Their primary product candidate, EDG-5506, completes Phase 1 clinical trial and aims to treat dystrophinopathies like Duchenne muscular dystrophy and Becker muscular dystrophy. The company also specializes in developing precision medicine product candidates that target specific muscle proteins and modulators to address genetically defined muscle disorders.